Novartis Korea to offer cash compensation program for leukemia patients in Korea

The Korea Orphan Drug Center said that those patients taking Glivec from this February will benefit from Novartis Korea's compensation program to cover patient's out-of-pocket of Glivec's treatment costs by ten percent in cash, provided that those who have received Glivec capsule 100mg and citizens in the low-income bracket have been excluded.

To that end, Novartis Korea will deposit to the ...